0.00%
150.00%
150.00%
1.25%
-70.98%
-93.16%
-96.79%
AI Spotlight on CNTG
Company Description
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide.It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors.The company also offers COVID-19 testing solutions, including PCR and antigen testing services.It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation.
Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Market Data
| Last Price | 0.33 |
| Change Percentage | 0.00% |
| Open | 0.43 |
| Previous Close | 0.33 |
| Market Cap ( Millions) | 9 |
| Volume | 7229138 |
| Year High | 1.53 |
| Year Low | 0.14 |
| M A 50 | 0.38 |
| M A 200 | 0.73 |
Financial Ratios
| FCF Yield | -188.48% |
| Dividend Yield | 0.00% |
| ROE | 0.00% |
| Debt / Equity | -317.77% |
| Net Debt / EBIDTA | 0.00% |
| Price To Book | 0 |
| Price Earnings Ratio | 0 |
| Price To FCF | -0.53 |
| Price To sales | 0 |
| EV / EBITDA | 0 |
News
- Dec -05 - CENTOGENE Announces Voting Results of Extraordinary General Meeting
- Nov -13 - CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
- Sep -25 - CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
- Aug -07 - CENTOGENE Receives Delisting Notice From Nasdaq
- Aug -01 - CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
- Jun -20 - C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
- May -31 - CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
- May -15 - CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
- May -15 - CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
- May -14 - CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
- May -10 - CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
- Apr -02 - CENTOGENE Receives Nasdaq Non-Compliance Notice
- Mar -19 - CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
- Feb -29 - CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRΞ± Deficiency
- Feb -28 - CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
- Feb -28 - CENTOGENE Explores Strategic Alternatives
- Jan -25 - CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
- Jan -24 - CENTOGENE Receives French Research Tax Credit Accreditation
- Jan -18 - CENTOGENE Announces Preliminary Full Year 2023 Revenue
- Dec -19 - CENTOGENE Announces Voting Results of Extraordinary General Meeting
Business Breakdown
Expected Mid-Term Growth
Segment nΒ°1 -> Diagnostics
Expected Growth : 10.43 %
What the company do ?
Centogene N.V.'s Diagnostics provides genetic testing and analysis for rare genetic disorders, enabling early diagnosis and personalized treatment for patients.
Why we expect these perspectives ?
Centogene N.V.'s diagnostics segment growth of 10.43% is driven by increasing demand for genetic testing, expansion into new markets, and strategic partnerships. The company's focus on rare genetic disorders and its proprietary CE-marked tests also contribute to growth. Additionally, investments in digital health and AI-powered diagnostics enhance the company's offerings, attracting more customers and driving revenue growth.
Segment nΒ°2 -> Pharmaceutical
Expected Growth : 10.43 %
What the company do ?
Centogene N.V.'s Pharmaceutical segment focuses on developing and commercializing rare disease therapies, leveraging its proprietary biomarker platform and expertise in genetic diagnostics.
Why we expect these perspectives ?
Centogene N.V.'s 10.43% growth in pharmaceuticals is driven by increasing demand for genetic diagnostics, expansion into new markets, and strategic partnerships. The company's unique genetic testing capabilities and growing database of genetic information also contribute to its growth. Additionally, the rising prevalence of genetic disorders and increasing adoption of precision medicine further fuel the segment's growth.
Centogene N.V. Products
| Product Range | What is it ? |
|---|---|
| CentoMD | CentoMD is a genetic diagnostic platform that provides a comprehensive genetic diagnosis for patients with rare genetic disorders. |
| CentoXome | CentoXome is a whole-exome sequencing test that analyzes a patient's entire protein-coding genome to identify genetic variations associated with rare diseases. |
| CentoArray | CentoArray is a genetic testing platform that uses microarray technology to detect chromosomal abnormalities and genetic variations associated with rare diseases. |
| CentoGenome | CentoGenome is a whole-genome sequencing test that analyzes a patient's entire genome to identify genetic variations associated with rare diseases. |
| CentoMetabolic | CentoMetabolic is a genetic testing platform that analyzes genes associated with inborn errors of metabolism, enabling early diagnosis and treatment of metabolic disorders. |
| CentoCardio | CentoCardio is a genetic testing platform that analyzes genes associated with cardiovascular disease, enabling early diagnosis and prevention of cardiovascular events. |
Centogene N.V.'s Porter Forces
Threat Of Substitutes
Centogene N.V. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the emergence of new technologies and competitors.
Bargaining Power Of Customers
Centogene N.V. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's unique offerings and expertise in rare genetic disorders give it a competitive advantage.
Bargaining Power Of Suppliers
Centogene N.V. relies on a few key suppliers for its operations, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.
Threat Of New Entrants
The genetic testing and diagnostics market has high barriers to entry, including significant capital requirements, regulatory hurdles, and the need for specialized expertise. This limits the threat of new entrants.
Intensity Of Rivalry
The genetic testing and diagnostics market is highly competitive, with several established players competing for market share. Centogene N.V. must continually innovate and differentiate itself to maintain its competitive edge.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 159.27% |
| Debt Cost | 3.95% |
| Equity Weight | -59.27% |
| Equity Cost | 0.60% |
| WACC | 5.93% |
| Leverage | -268.73% |
Centogene N.V. : Quality Control
Centogene N.V. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CBAV.MC | ClΓnica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics β¦ |
| VOX.WA | Voxel S.A. operates a network of diagnostic imaging laboratories. Its diagnostic imaging services include magnetic resonance imaging scans, computed tomography scans, positron emission tomography, and single photon emission computed tomography. β¦ |
| VIMIAN.ST | Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription β¦ |
| SLV.WA | Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. β¦ |
| LBIRD.PA | Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, β¦ |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
π₯
ClΓnica Baviera
A-Score
1-Year Total Return ->
π₯
Voxel
A-Score
1-Year Total Return ->
π₯
Selvita
A-Score
1-Year Total Return ->
4
Centogene
A-Score
1-Year Total Return ->
5
Vimian Group
A-Score
1-Year Total Return ->
6
